CORONARY ARTERY BYPASS GRAFTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Coronary Artery Bypass Grafting Market, By Technology (Off-pump CABG, On-pump CABG, and Others), By Product (Grafts, Retractors, Heart positioners, Tissue stabilizers, and Others), By End User (Hospitals, Cardiology Clinics, Ambulatory surgical centers, Academic & Research institute, and Other), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In April 2024,The Society of Thoracic Surgeons (STS) introduced new risk calculators for isolated tricuspid valve repair and replacement, surgical aortic valve replacement (SAVR) following prior transcatheter aortic valve replacement (TAVR), and multi-valve surgeries with or without coronary artery bypass grafting (CABG)
In August 2022, Medtronic plc, a medical device company, announced its acquisition of Affera, Inc., enhancing its cardiac ablation portfolio with its first comprehensive cardiac mapping and navigation platform. This new platform integrates a distinctive combination of diagnostic tools, focal pulsed field ablation, and radiofrequency ablation solutions.
In January 2022, Humacyte, Inc. reported positive results from a preclinical study of its small-diameter Human Acellular Vessel (HAV) used in coronary artery bypass grafting (CABG). The HAV maintained patency and showed effective host-cell remodeling in a non-human primate model. CABG, performed around 400,000 times yearly in the U.S., typically uses saphenous vein grafts, which have a 30% failure rate within a year.